- Home
- ALXN
ALXN
Alexion Pharmaceuticals, Inc.
117.93
+
0.69
0.59%
18 x 117.95
11 x 118.00
bid
ask
15 @ 04:00 PM
117.93+0.00 (0.00%)
Bearish
123
Bullish
456
sentiment
116.81
day range
118.96
92.56
52 week range
141.86
04:00 PM
V: 692.56K
C: 117.93
L: 116.81
H: 118.96
O: 117.34
loading chart ...
Prev Close117.24
Open117.34
Low116.81
High118.96
Volume692.56K
Avg. Volume1.38M
Market Cap26.44B
Inst. Own96.77%
Beta1.79
Short Ratio2.77
Div & Yield /
EPS1.86
P/E63.34
1yr Target117.93
Ytd Return117.93
1yr Return117.93
50-day MA126.69
200day MA123.99
^DJI
Dow Jones Industrial Average
26089.61
05:14 PM
-
17.19
0.07%
^IXIC
NASDAQ Composite
7796.66
05:15 PM
-
40.47
0.52%
^GSPC
S&P 500
2886.98
05:14 PM
-
4.66
0.16%
AAPL
192.86
+0.12 (0.06%)
Apple Inc.
192.74
9 @ 04:00 PM
9 x 192.70
8 x 192.86
-
1.41
0.73%
GOOG
1085.35
+0.00 (0.00%)
Alphabet Inc.
1085.35
24 @ 04:00 PM
8 x 1084.90
40 x 1085.97
-
3.42
0.31%
AMZN
1869.00
-0.67 (0.04%)
Amazon.com, Inc.
1869.67
14 @ 04:00 PM
10 x 1869.50
18 x 1870.37
-
0.63
0.03%
MSFT
132.45
+0.00 (0.00%)
Microsoft Corporation
132.45
11 @ 04:00 PM
14 x 132.41
8 x 132.36
+
0.13
0.10%
FB
182.90
+1.57 (0.87%)
Facebook, Inc.
181.33
13 @ 04:00 PM
14 x 182.69
12 x 182.90
+
3.86
2.18%
BABA
158.00
-0.10 (0.06%)
Alibaba Group Holding Limited
158.10
16 @ 04:01 PM
13 x 158.01
18 x 158.34
-
2.23
1.39%
NFLX
339.60
-0.13 (0.04%)
Netflix, Inc.
339.73
8 @ 04:00 PM
8 x 339.35
8 x 339.73
-
3.70
1.08%
TSLA
214.99
+0.07 (0.03%)
Tesla, Inc.
214.92
8 @ 04:00 PM
8 x 214.84
8 x 214.95
+
1.01
0.47%
NVDA
143.85
-0.79 (0.55%)
NVIDIA Corporation
144.64
10 @ 04:00 PM
9 x 144.01
11 x 144.14
-
3.62
2.44%
AMD
30.18
-0.18 (0.59%)
Advanced Micro Devices, Inc.
30.36
192 @ 04:00 PM
22 x 30.20
362 x 30.16
-
1.03
3.28%
MU
32.66
+0.00 (0.00%)
Micron Technology, Inc.
32.66
26 @ 04:00 PM
12 x 32.66
40 x 32.73
-
0.72
2.16%
SPY
289.35
+0.12 (0.04%)
SPDR S&P 500 ETF
289.23
16 @ 04:00 PM
9 x 289.58
22 x 0.00
-
0.35
0.12%
TQQQ
57.55
-0.08 (0.14%)
ProShares UltraPro QQQ
57.63
8 @ 04:00 PM
8 x 57.60
8 x 57.60
-
0.76
1.30%
BRK-A
- ()
Berkshire Hathaway Inc.
308206.00
8 @ 04:00 PM
8 x 308380.03
8 x 308562.75
+
761.00
0.25%
| Day Gain | 13927.99 | |
| Gain | ||
| Mkt Val | ||
| Costs | ||
| Cash | ||
| Portfolio | ||
| Realized | ||
| Dividend |
-
Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) Expected to Announce Quarterly Sales of $1.17 Billion
Tech Know Bits •0
Views -
Looking at the Levels on Shares of Alexion Pharm Inc (ALXN)
Tyndall Times •0
Views -
Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) Director Bros. Advisors Lp Baker Sells 300,000 Shares
Mayfield Recorder •0
Views -
0
Views -
0
Views -
0
Views -
Pounding the Pavement on Shares of Alexion Pharmaceuticals, Inc. (NasdaqGS:ALXN), Southwest Airlines Co. (NYSE:LUV)
Wagner Review •0
Views -
0
Views -
0
Views -
Alexion Pharma (ALXN) Reports Positive Phase 3 Extension Data for ULTOMIRIS (ravulizumab) in Patients with Paroxysmal Nocturnal Hemoglobinuria at EHA 2019 Meetings
StreetInsider.com •0
Views -
0
Views -
0
Views -
Peeling The Layers Back on Valuation For Alexion Pharmaceuticals, Inc. (NasdaqGS:ALXN), Foot Locker, Inc. (NYSE:FL)
Wagner Review •0
Views -
0
Views -
0
Views -
Digging Into the Numbers for Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) as Monthly Performance of -4.18519695 Shows Signs of Volatility
Wagner Review •0
Views -
0
Views -
Alexion Pharm Inc (ALXN) Chikou Sliding Below the Tenkan
Auburn Digest •0
Views -
Alpha Quant Advisors LLC Invests $291000 in Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) Stock
Slater Sentinel •0
Views -
Meiji Yasuda Life Insurance Co Has $1.09 Million Holdings in Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN)
Mayfield Recorder •0
Views -
Alexion Pharm Inc (ALXN): Share Price Drips Lower -11.05%
Auburn Digest •0
Views -
0
Views -
Piotrioski's F-Score in Focus For These Stocks: NetApp, Inc. (NasdaqGS:NTAP), Alexion Pharmaceuticals, Inc. (NasdaqGS:ALXN)
Wagner Review •0
Views -
0
Views -
0
Views -
Alexion Pharmaceuticals, Inc.- DirectorsTalk Interviews
Consenus Indicates Potential 40.3% Upside •0
Views -
0
Views -
Wetherby Asset Management Inc. Has $502,000 Position in Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN)
Mayfield Recorder •0
Views -
What's Unfolding For Shares of Alexion Pharmaceuticals, Inc. (NasdaqGS:ALXN)
Avondale Advocate •0
Views -
0
Views -
Avestar Capital LLC Acquires 81 Shares of Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN)
Tech Know Bits •0
Views
Alexion Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes various therapeutic products. The company offers ULTOMIRIS (ALXN1210/ravulizumab-cwvz), a monoclonal antibody for the treatment of paroxysmal nocturnal hemoglobinuria (PNH), a genetic blood disorder; and Soliris (eculizumab), a monoclonal antibody for the treatment of PNH, atypical hemolytic uremic syndrome (aHUS), and generalized myasthenia gravis. It also provides Strensiq (asfotase alfa), a targeted enzyme replacement therapy for patients with hypophosphatasia; and Kanuma (sebelipase alfa) for the treatment of patients with lysosomal acid lipase deficiency. In addition, the company conducts Phase III clinical trials for ALXN 1210 (IV) that is in Phase III clinical trials for the treatment of PNH and aHUS; ALXN1210 (Subcutaneous), which is in Phase I for PNH and aHUS; and Soliris (eculizumab) for the treatment of myasthenia gravis and neuromyelitis optica spectrum disorder. Further, it develops ALXN1840 (WTX101) that is in Phase III clinical trials for the treatment of Wilson disease; and ALXN1830 (SYNT001), which is in Phase II clinical trials for the treatment of warm autoimmune hemolytic anemia. The company serves distributors, pharmacies, hospitals, hospital buying groups, and other healthcare providers in the United States, Europe, the Asia Pacific, and internationally. Alexion Pharmaceuticals, Inc. has collaboration and license agreement with Halozyme Therapeutics, Inc. to use drug-delivery technology in the development of subcutaneous formulations for its portfolio of products; collaboration with Dicerna Pharmaceuticals, Inc. to discover and develop RNAi therapies for complement-mediated diseases, as well as with Zealand Pharma A/S; strategic agreement with Caelum Biosciences, Inc. to advance the development of CAEL-101 for light chain (AL) amyloidosis; and partnership with Affibody AB. The company was founded in 1992 and is headquartered in Boston, Massachusetts.
Financials
Notes
